• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Biotechnology’s Role in Improving Stroke Outcomes

    CEO Spotlight: Marc Kikuchi

    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex

    Schott Creates Stand-Alone Company for its Pharma Business

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Marken to Acquire Medical Courier Business of Cedra Express

    Porton’s New Crystallization and Drug Product Facility

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Woodstock Sterile Solutions Fills Two Leadership Roles

    SmartLabs To Open New Facility in Philadelphia
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Marken to Acquire Medical Courier Business of Cedra Express

    5 Key Features of Agile Pharmaceutical Packaging Supply Chains That Drive Results

    Novavax Expands Manufacturing Agreement with SK bioscience

    Lonza Continues to Lead the Market with Innovative Hard Empty Capsules

    Sharp Expands Reach to China Through Partnership with ClinsChain
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Thermo Fisher Expands NY Cell Culture Media Manufacturing Site

    Thorne HealthTech, AstraZeneca Entend AI Discovery Alliance

    Gilead Sciences to Acquire MiroBio for $405M

    Amgen to Acquire ChemoCentryx for $3.7B

    BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Chime Biologics Receives Commercial Manufacturing License

    Automation Is Key to Meeting Demands in Pharmacovigilance

    UBC Acquires Examoto

    Responding to Consumer Complaints While Working with CMOs

    WuXi Vaccines Receives GMP Certificate from HPRA
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Vector Partners Limited

    Kyongbo Pharmaceutical

    Quotient Sciences

    Aphena Pharma Solutions

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Vector Partners Limited

    Kyongbo Pharmaceutical

    Quotient Sciences

    Aphena Pharma Solutions

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Overcoming Preclinical Drug Development Hurdles

    Aidan Synnott of Charles River Laboratories discusses the latest developments in oncology research models

    Overcoming Preclinical Drug Development Hurdles
    Related CONTENT
    • Altasciences Acquires Calvert Laboratories
    • Charles River Laboratories
    • TCG Lifesciences
    • Pierre Fabre Buys Igenica Immuno-oncology Assets
    • BMS, Calithera Biosciences Expand Clinical Collaboration
    Kristin Brooks, Contract Pharma05.02.17
    While major progress has been achieved in cancer research and development, the majority of new therapies continue to fail in human trials, despite showing promise in preclinical testing. Charles River Labs is working to help combat this issue with novel animal research models to address the challenges cancer drugs face in development.

    Aidan Synnott, Ph.D., Executive Director, Discovery Oncology at Charles River Laboratories, discusses the latest developments in oncology research models, as well as the R&D trends impacting drug discovery and the greatest motivators for preclinical outsourcing in today’s market. – KB
     
    Contract Pharma: What are the most significant pharma/biopharma R&D trends impacting drug discovery and development?

    Aidan Synnott: The industry is undergoing something of an immunological awakening because of the success of immunotherapies in treating cancer. We have seen a redirection of resources and investment into oncology research at the expense of other indications. The revolutionizing impact of this breakthrough and the consequent increased investment has broadened drug makers’ horizons and emboldened them to try out new paradigms that go way beyond the traditional chemotherapeutics and targeted therapies that were dominant. Although it started in cancer, the trend has spread to metabolic diseases, CNS and other therapeutic areas. This seismic shift has created a need for more varied and specialized preclinical assays and models.

    Another massive trend is the attempt to harness big data to increase the translatability of therapeutic assets identified in early drug discovery. We see an ever-tightening relationship between preclinical research and the clinic.

    CP: What service areas are you seeing an increased demand for and from what sectors?

    AS: As the Big Pharma model of producing a drug from soup to nuts has proven to be less effective at getting novel drugs to market, the drug discovery and development process has become fragmented. This has led to an increased need for experts who know how to move a drug from one phase to the next and provide integrated, consultative guidance. Additionally, as the science and regulatory requirements get more complex there is a need for more depth of expertise in each of these segments, which plays to the strengths of large CROs, that work with most of the industry at some stage of the process. The shift in the types of companies who are being truly innovative in the industry has led to a diversification of sectors to include venture capital-funded start-ups, academic spin-offs and “Two Men and a Molecule”-type companies.

    CP: What do you see as the greatest motivators for preclinical outsourcing in today’s market?

    AS: Biopharma companies have long been comfortable outsourcing clinical and preclinical toxicology work, but they are also starting to understand that they can trust earlier stage work to CROs as well. Their historic reluctance has stemmed from the greater need for secrecy and a belief that no one can do the work as well as their scientists. With an increase in the quality of outsourcing options, even drug makers with in-house capabilities are learning that it can be a lot more efficient and cost-effective to work with a CRO. A benefit of working with a large CRO is that they run hundreds more of the niche assays needed to identify novel drugs and prove their efficacy than even Big Pharma due to greater experience and expertise with those tools. An added spur has been the increase in start-ups and virtual companies due to increased investment in biotech and the recent downsizing trends in the industry, freeing up scientists to pursue their own innovative projects.  

    CP: What are some of latest developments in oncology research?

    AS: Immuno-oncology research is still leading the preclinical space. A lot of the work being done focuses on combining therapeutic agents that are not necessarily immunomodulatory with proven immunotherapies, such as checkpoint inhibitors. Drug makers are looking either to enhance immunogenicity of tumors to make them more susceptible to immunotherapies or to mitigate their toxic side-effects. A considerable number of these combination drugs are being repurposed either from another therapeutic indication (e.g. autoimmune diseases) or from a frozen or terminated pipeline that already has associated clinical data. Cellular therapies are more niche due to the complex risk factors associated with them but still a strong R&D interest.

    Other strong niches in the non-immune space include epigenetic approaches and HDAC inhibitors. Targeted therapies including ADCs are still getting their fair share of attention too, but everyone is more aware of the immune environment and its potential impact than they used to be.

    CP: How can these research models help streamline/advance drug development?

    AS: The most dramatic increase in demand since last year’s AACR has been for mouse models with a humanized system, imaging and in vitro assays.

    Imaging demand tends to be for bioluminescent and fluorescent modalities and has been stimulated by the belief that running tumor models orthotopically rather than subcutaneously allows a greater, more clinically relevant interaction with the immune system. In vitro assays have seen renewed interest because of improved technology such as high-content imaging, which allows meaningful observation of the mechanism of action of biologics. Another point of interest is the co-culturing of immune cells with tumor cells prior to research moving to the in vivo stage.

    Historically, the biggest barriers to the advent of humanized models was the high price point and unrealistic expectations about their potential to be a “human in a mouse.” We have reached a point where the industry is starting to understand the potential of humanized models, while accepting their limitations. The increase in the variety and availability of the models has lowered the price point. Meanwhile, researchers are starting to understand the scope and nature of the questions they can be used to answer. We are still seeing a rising demand for syngeneic mouse models but it is only a matter of time before they are overtaken by humanized models.



     
    Aidan Synnott is the Executive Director of Discovery Oncology at Charles River, where he oversees the company’s global oncology services operations, running over 2000 studies annually.
    Related Searches
    • cancer
    • Outsourcing
    • in vivo
    • immunotherapies
    Suggested For You
    Altasciences Acquires Calvert Laboratories Altasciences Acquires Calvert Laboratories
    Charles River Laboratories Charles River Laboratories
    TCG Lifesciences TCG Lifesciences
    Pierre Fabre Buys Igenica Immuno-oncology Assets Pierre Fabre Buys Igenica Immuno-oncology Assets
    BMS, Calithera Biosciences Expand Clinical Collaboration BMS, Calithera Biosciences Expand Clinical Collaboration
    Sanofi and Exscientia Pen €250M Drug Discovery Deal Sanofi and Exscientia Pen €250M Drug Discovery Deal
    Takeda Inks $100M Pact With GammaDelta Takeda Inks $100M Pact With GammaDelta
    Regeneron, SillaJen in Clinical and Supply Pact Regeneron, SillaJen in Clinical and Supply Pact
    Nimbus Therapeutics, Charles River in Strategic R&D Alliance Nimbus Therapeutics, Charles River in Strategic R&D Alliance
    Charles River Launches Oncology Research Model Charles River Launches Oncology Research Model
    Vedantra Forms Research Collaboration with Neon Therapeutics Vedantra Forms Research Collaboration with Neon Therapeutics
    Charles River, Chiesi Extend Drug Discovery Alliance Charles River, Chiesi Extend Drug Discovery Alliance
    BASI Appoints Preclinical Services SVP BASI Appoints Preclinical Services SVP
    Generic Drug Trends Generic Drug Trends
    AMRI in Drug Discovery Alliance AMRI in Drug Discovery Alliance

    Related Breaking News

    • Breaking News | Industry News
      Altasciences Acquires Calvert Laboratories

      Altasciences Acquires Calvert Laboratories

      Now has presence on U.S. East Coast; increases small molecule expertise.
      Tim Wright, Editor, Contract Pharma 05.07.21

    • Charles River Laboratories

      Charles River Laboratories

      ...
      Genevieve Glazier, Director Safety Assessment Marketing 12.07.20

    • TCG Lifesciences

      TCG Lifesciences

      ...
      Chris Verbicky, VP, Business Development & Marketing 11.08.18


    • Breaking News | Drug Development | Industry News | Preclinical Outsourcing
      Pierre Fabre Buys Igenica Immuno-oncology Assets

      Pierre Fabre Buys Igenica Immuno-oncology Assets

      Deal reinforces Pierre Fabre’s pipeline in oncology, its primary R&D focus area
      05.24.17

    • Collaborations & Alliances | Drug Development
      BMS, Calithera Biosciences Expand Clinical Collaboration

      BMS, Calithera Biosciences Expand Clinical Collaboration

      Will evaluate Opdivo in combination with CB-839 in NSCLC and Melanoma
      05.10.17

    Loading, Please Wait..
    Trending
    • Gilead Sciences To Acquire MiroBio For $405M
    • Amgen To Acquire ChemoCentryx For $3.7B
    • BioNTech, Genmab Expand Global Strategic Oncology Collaboration
    • Bayer Opens New Research And Innovation Center At Kendall Square
    • Datwyler To Double Capacity At Production Ops In Pune
    Breaking News
    • BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    • Schott Creates Stand-Alone Company for its Pharma Business
    • Marken to Acquire Medical Courier Business of Cedra Express
    • Porton’s New Crystallization and Drug Product Facility
    • Thermo Fisher Expands NY Cell Culture Media Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • Biotechnology’s Role in Improving Stroke Outcomes
    • CEO Spotlight: Marc Kikuchi
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    3i Solutions Announces New Leadership Positions
    INS Nutra Opens Gummy Manufacturing Facility
    Vital Nutrients Launches First Vegan Omega Supplement with SPMs
    Coatings World

    Latest Breaking News From Coatings World

    Custom Cars Featuring PPG DELTRON Refinish System Take Awards at Goodguys 24th Summit
    HGTV Home by Sherwin-Williams Announces 2023 Color Collection of the Year
    BASF to Produce More Specialty Pyrrolidones in North America
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Elizabeth Coleon Joins Withings as Chief Marketing Officer
    U.K. Strengthens Medical Device Regulations
    Fujirebio Acquires ADx NeuroSciences
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    Schott Creates Stand-Alone Company for its Pharma Business
    Marken to Acquire Medical Courier Business of Cedra Express
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Body Shop Expands Partnership with Uber
    COSRX Launches Vitamin E Vitalizing Sunscreen
    Weekly Recap: Kylie Makeup Lab Controversy, Glossier Pivots to Retail and Wholesale & More
    Happi

    Latest Breaking News From Happi

    Dry Shampoo Brand Batiste Teams Up with Barry's Boot Camp to Give Consumers Post-Workout Refresh
    Watsons China Launches Health Care Zone Prompted by the Covid-19 Pandemic
    Earth Therapeutics Celebrates National CBD Day with Foot Balm-Enriched CBD
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: Zeller+Gmelin, Epple Druckfarben Lead This Week’s News Stories
    A-Flex Label Adds Epson SurePress UV Digital Label Press
    Ball Announces 2Q 2022 Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eukalin acquires Adhesives Specialists
    EyeC unveils new inspection products
    Errol Moebius named VP of IST America
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: A New Day for Hygiene, Glatfelter Reports Q2 Results & More
    Dyper Achieves B Corp Certification
    Edgewell’s Sales Grow
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Inc. Reports Q2 2022 Financial Results
    Solid Growth Ahead for Carpal Tunnel Release Systems Sector
    ODT's Most-Read Stories This Week—Aug. 6
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: STMicroelectronics, NextFlex and onsemi Top This Week’s Stories
    Zebra Technologies Reports 2Q 2022 Results
    InnovationLab Demonstrates New PCB Production Method Based on Additive Manufacturing

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login